Skip to Content

Genelink Inc GNLKQ

Morningstar Rating
$0.00 0.00 (900.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GNLKQ is trading at a 26% premium.
Price
$0.00
Fair Value
$3.76
Uncertainty
Extreme
1-Star Price
$6.64
5-Star Price
$6.66
Economic Moat
Qrfmxy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNLKQ is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.00
Market Cap
$2,650.19
Volume/Avg
360,235 / 358,210

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
GNLKQ
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
GNLKQ
Quick Ratio
0.12
Current Ratio
0.34
Interest Coverage
−8.02
Quick Ratio
No chart available

Profitability

Metric
GNLKQ
Return on Assets (Normalized)
−147.02%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FnpvwcngcxHrtxp$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
HcgnnmkqMltcfdq$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
MfkzwvzXjhtgt$121.2 Bil
Moderna Inc
MRNA
NzhstvszJrr$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
VjcdbpxxTtbkkx$33.0 Bil
argenx SE ADR
ARGX
GjsqpxkMjrv$27.9 Bil
BioNTech SE ADR
BNTX
XyslkmsWgshw$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
TktvwggmBpvphw$16.1 Bil
United Therapeutics Corp
UTHR
ZkdwhpjhfYswv$14.3 Bil
Incyte Corp
INCY
VhmjjxbsKlylt$12.5 Bil

Sponsor Center